Progression of T2DM is widely accepted to be contributed by two main components: beta cell function deterioration where insulin secretion is impaired and insulin resistance where insulin physiological response is reduced. Insulin resistance and beta cell function will be estimated through a mathematical model, homeostasis model assessment. Fasting insulin and C-peptide will be measured using liquid chromatography tandem mass spectrometry. Insulin resistance and beta cell function is then compared with the glycaemic control, HbA1C.
Primary objective • To investigate the association between the estimation of insulin resistance and beta cell function through homeostasis model assessment with HbA1C among oral anti-diabetics treatment non-responder. Secondary Objectives * To compare the insulin resistance and beta cell function between the OAD treatment responders (negative control) and non-responders * To investigate the relationship between plasma level of metformin and gliclazide with the estimation of beta cell function and insulin resistance * To identify the proportion of patients with high insulin resistance and proportion of patients with low beta cell function * To identify difference in insulin resistance and beta cell function of different ethnic groups in Sarawak * To compare insulin resistance with cardiovascular disease risk using Framingham Risk Score and ASCVD risk estimation
Study Type
OBSERVATIONAL
Enrollment
255
Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
Clinical Research Centre, Sarawak General Hospital
Kuching, Sarawak, Malaysia
HOMA estimation of insulin resistance and beta cell function
Insulin resistance and beta cell function is estimated through homeostasis model assessment
Time frame: 1 day
HbA1C
Glycaemic control of subjects assessed through HbA1C
Time frame: 1 day
Medication adherence
Assessed using Malaysian Medication Adherence Scale
Time frame: 1 day
Plasma metformin level
Measured using LCMS
Time frame: 1 day
Plasma gliclazide level
Measured using LCMS
Time frame: 1 day
Cardiovascular risk estimation
Framingham risk score and ASCVD risk estimation
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.